- Home
- ACIU vs NBTX Comparison
ACIU vs NBTX Comparison
Compare ACIU & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- NBTX
- Stock Information
- Founded
- ACIU 2003
- NBTX 2003
- Country
- ACIU Switzerland
- NBTX France
- Employees
- ACIU N/A
- NBTX N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- ACIU Health Care
- NBTX Health Care
- Exchange
- ACIU Nasdaq
- NBTX Nasdaq
- Market Cap
- ACIU 168.7M
- NBTX 167.8M
- IPO Year
- ACIU 2016
- NBTX 2020
- Fundamental
- Price
- ACIU $2.07
- NBTX $4.53
- Analyst Decision
- ACIU Strong Buy
- NBTX Strong Buy
- Analyst Count
- ACIU 1
- NBTX 1
- Target Price
- ACIU $12.00
- NBTX $8.00
- AVG Volume (30 Days)
- ACIU 119.1K
- NBTX 9.1K
- Earning Date
- ACIU 08-05-2025
- NBTX 04-02-2025
- Dividend Yield
- ACIU N/A
- NBTX N/A
- EPS Growth
- ACIU N/A
- NBTX N/A
- EPS
- ACIU N/A
- NBTX N/A
- Revenue
- ACIU $32,014,254.00
- NBTX N/A
- Revenue This Year
- ACIU N/A
- NBTX N/A
- Revenue Next Year
- ACIU $533.21
- NBTX $221.06
- P/E Ratio
- ACIU N/A
- NBTX N/A
- Revenue Growth
- ACIU 91.20
- NBTX N/A
- 52 Week Low
- ACIU $1.43
- NBTX $2.76
- 52 Week High
- ACIU $4.37
- NBTX $6.00
- Technical
- Relative Strength Index (RSI)
- ACIU 59.88
- NBTX 53.05
- Support Level
- ACIU $1.79
- NBTX $4.31
- Resistance Level
- ACIU $2.10
- NBTX $5.76
- Average True Range (ATR)
- ACIU 0.17
- NBTX 0.24
- MACD
- ACIU 0.00
- NBTX -0.09
- Stochastic Oscillator
- ACIU 71.93
- NBTX 22.15
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.